These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10233802)

  • 1. The PSA revisited: potentials and pitfalls.
    Harv Mens Health Watch; 1999 Jun; 3(11):1-5. PubMed ID: 10233802
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
    Maksimov VA; Kamalov AA; Karpov VK; Riaboĭ AV; Prokhorov AV
    Urologiia; 2001; (2):37-40. PubMed ID: 11490716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSA scores: should we use a lower threshold?
    Carter HB
    Johns Hopkins Med Lett Health After 50; 2004 Oct; 17(8):6. PubMed ID: 15602780
    [No Abstract]   [Full Text] [Related]  

  • 5. [Early detection of prostatic carcinoma: Is PSA screening suitable?].
    Kaulen H
    Dtsch Med Wochenschr; 2003 May; 128(18):977. PubMed ID: 12755136
    [No Abstract]   [Full Text] [Related]  

  • 6. Making sense of PSA.
    Thompson IM
    Health News; 2001 Apr; 7(4):3. PubMed ID: 11303477
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed].
    Bratt O; Björk T
    Lakartidningen; 2007 Nov 14-20; 104(46):3460-4. PubMed ID: 18072615
    [No Abstract]   [Full Text] [Related]  

  • 8. [Present-day possibilities of prostate cancer screening in patients with benign prostatic hyperplasia before and after surgical treatment].
    Pushkar' DIu; Rasner PI; Skobelev PP
    Urologiia; 2001; (6):48-54. PubMed ID: 11785083
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy.
    Elmansy HM; Elzayat EA; Sampalis JS; Elhilali MM
    Urology; 2009 Nov; 74(5):1105-10. PubMed ID: 19773035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSA and prostate cancer screening: the challenge of the new millennium.
    Bjartell A
    Eur Urol; 2007 Nov; 52(5):1284-6. PubMed ID: 17720305
    [No Abstract]   [Full Text] [Related]  

  • 11. PSA screening.
    Cohen S; Schiff S; Kelty P
    Med Health R I; 2005 Mar; 88(3):90-1. PubMed ID: 15915782
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostate specific antigen (PSA)-based screening.
    Suzuki H; Flanigan RC; Okuyama A;
    Int J Urol; 2008 Sep; 15(9):757-62. PubMed ID: 18786202
    [No Abstract]   [Full Text] [Related]  

  • 13. [Based on current knowledge the introduction of the PSA screening for prostatic cancer is unethical].
    Krantz I; Sachs L; Ahlberg BM; Nordin P; Nilstun T
    Lakartidningen; 2005 Sep 5-11; 102(36):2498-500. PubMed ID: 16196436
    [No Abstract]   [Full Text] [Related]  

  • 14. A study of the correlation of prostatic pathology and serum prostate-specific antigen (PSA) levels: a perspective from Papua New Guinea.
    Murthy DP; Ray U; Morewaya J; SenGupta SK
    P N G Med J; 1998 Jun; 41(2):59-64. PubMed ID: 10934545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of prostatic massage on serum complexed prostate-specific antigen levels.
    Tarhan F; Orçun A; Küçükercan I; Camursoy N; Kuyumcuoğlu U
    Urology; 2005 Dec; 66(6):1234-8. PubMed ID: 16360449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The usefulness of prostate specific antigen density as a screening method for prostatic carcinoma.
    Chakrabarti S; Raha K; Bhunia CL; Bhattachary DK
    J Indian Med Assoc; 2001 Nov; 99(11):627-8, 630. PubMed ID: 12022203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age-related reference intervals for free and total prostate-specific antigen in a Singaporean population.
    Saw S; Aw TC
    Pathology; 2000 Nov; 32(4):245-9. PubMed ID: 11186419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.
    Aksoy Y; Oral A; Aksoy H; Demirel A; Akcay F
    Ann Clin Lab Sci; 2003; 33(3):320-3. PubMed ID: 12956448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
    Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
    Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan.
    Ito K; Kakehi Y; Naito S; Okuyama A;
    Int J Urol; 2008 Sep; 15(9):763-8. PubMed ID: 18786203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.